research use only
Cat.No.S9920
| Related Targets | EGFR JAK Pim |
|---|---|
| Other STAT Inhibitors | Napabucasin (BBI608) Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) C188-9 (TTI-101) SH-4-54 BP-1-102 AS1517499 Nifuroxazide HO-3867 |
|
In vitro |
DMSO
: 75 mg/mL
(199.21 mM)
Water : 25 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 376.47 | Formula | C11H16NO2PS2.C4H9NO |
Storage (From the date of receipt) | 3 years -20°C powder, oxygen-free (long-term storage) |
|---|---|---|---|---|---|
| CAS No. | 106740-09-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=CC=C(C=C1)[P](S)(=S)N2CCOCC2.C3COCCN3 | ||
| Targets/IC50/Ki |
STAT3
|
|---|---|
| In vitro |
GYY4137 (400-800 µM) causes concentration-dependent killing of seven different human cancer cell lines (HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11 and U2OS) but does not affect survival of normal human lung fibroblasts (IMR90, WI-38). |
| In vivo |
In the complete Freund's adjuvant (CFA)-treated mouse, GYY4137 injected 1 hr prior to CFA increased knee joint swelling while an anti-inflammatory effect, as demonstrated by reduced synovial fluid myeloperoxidase (MPO) and N-acetyl-β-D-glucosaminidase (NAG) activity and decreased TNF-α, IL-1β, IL-6 and IL-8 concentration, is apparent when this compound was injected 6 hrs after CFA. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.